^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | ifosfamide (Bifunctional alkylating agent) + pegylated liposomal doxorubicin (Topoisomerase II inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study
Published date:
11/04/2022
Excerpt:
This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)....Exploratory biomarker analysis suggested NF1 single-nucleotide variant was associated with poor OS (P < 0.0001) and PFS (P = 0.044).
DOI:
https://doi.org/10.1158/1078-0432.CCR-22-1785
Trial ID:
